
    
      The efficacy of an adjuvanted A(H1N1)v influenza vaccine in HIV-infected and immunosuppressed
      patients is unknown. Therefore we aim to investigate the immunoresponse as assessed by a
      anti-hemagglutinin assay before, 21 days after the first and 21 days after the second
      vaccination. The safety of the vaccination will be recorded by a standardized questionaire.
    
  